Machine learning models are often personalized by using group attributes that encode personal characteristics (e.g., sex, age group, HIV status). In such settings, individuals expect to receive more accurate predictions in return for disclosing group attributes to the personalized model. We study when we can tell that a personalized model upholds this principle for every group who provides personal data. We introduce a metric called the benefit of personalization (BoP) to measure the smallest gain in accuracy that any group expects to receive from a personalized model. We describe how the BoP can be used to carry out basic routines to audit a personalized model, including: (i) hypothesis tests to check that a personalized model improves performance for every group; (ii) estimation procedures to bound the minimum gain in personalization. We characterize the reliability of these routines in a finite-sample regime and present minimax bounds on both the probability of error for BoP hypothesis tests and the mean-squared error of BoP estimates. Our results show that we can only claim that personalization improves performance for each group who provides data when we explicitly limit the number of group attributes used by a personalized model. In particular, we show that it is impossible to reliably verify that a personalized classifier with $k \geq 19$ binary group attributes will benefit every group who provides personal data using a dataset of $n = 8\times10^9$ samples -- one for each person in the world.

Alzheimer's Disease (AD) is marked by significant inter-individual variability in its progression, complicating accurate prognosis and personalized care planning. This heterogeneity underscores the critical need for predictive models capable of forecasting patient-specific disease trajectories. Artificial Intelligence (AI) offers powerful tools to address this challenge by analyzing complex, multi-modal, and longitudinal patient data. This paper provides a comprehensive survey of AI methodologies applied to personalized AD progression prediction. We review key approaches including state-space models for capturing temporal dynamics, deep learning techniques like Recurrent Neural Networks for sequence modeling, Graph Neural Networks (GNNs) for leveraging network structures, and the emerging concept of AI-driven digital twins for individualized simulation. Recognizing that data limitations often impede progress, we examine common challenges such as high dimensionality, missing data, and dataset imbalance. We further discuss AI-driven mitigation strategies, with a specific focus on synthetic data generation using Variational Autoencoders (VAEs) and Generative Adversarial Networks (GANs) to augment and balance datasets. The survey synthesizes the strengths and limitations of current approaches, emphasizing the trend towards multimodal integration and the persistent need for model interpretability and generalizability. Finally, we identify critical open challenges, including robust external validation, clinical integration, and ethical considerations, and outline promising future research directions such as hybrid models, causal inference, and federated learning. This review aims to consolidate current knowledge and guide future efforts in developing clinically relevant AI tools for personalized AD prognostication.

Machine learning models are often personalized by using group attributes that encode personal characteristics (e.g., sex, age group, HIV status). In such settings, individuals expect to receive more accurate predictions in return for disclosing group attributes to the personalized model. We study when we can tell that a personalized model upholds this principle for every group who provides personal data. We introduce a metric called the benefit of personalization (BoP) to measure the smallest gain in accuracy that any group expects to receive from a personalized model. We describe how the BoP can be used to carry out basic routines to audit a personalized model, including: (i) hypothesis tests to check that a personalized model improves performance for every group; (ii) estimation procedures to bound the minimum gain in personalization.

Chronic stress can significantly affect physical and mental health. The advent of wearable technology allows for the tracking of physiological signals, potentially leading to innovative stress prediction and intervention methods. However, challenges such as label scarcity and data heterogeneity render stress prediction difficult in practice. To counter these issues, we have developed a multimodal personalized stress prediction system using wearable biosignal data. We employ self-supervised learning (SSL) to pre-train the models on each subject's data, allowing the models to learn the baseline dynamics of the participant's biosignals prior to fine-tuning the stress prediction task. We test our model on the Wearable Stress and Affect Detection (WESAD) dataset, demonstrating that our SSL models outperform non-SSL models while utilizing less than 5% of the annotations. These results suggest that our approach can personalize stress prediction to each user with minimal annotations. This paradigm has the potential to enable personalized prediction of a variety of recurring health events using complex multimodal data streams.

Asia is leading the pack in AI business deployment compared to less than a third for US companies. The adoption rate in the rest of the world remains low, as firms do not understand the deployment of AI¹ in their operations. The surveillance behavior of Chinese firms continues and contravenes privacy. MIT's decision to end its collaboration with iFlytek¹⁰ from China makes sense and will set the trend for other companies. Artificial intelligence does not have to hurt people but rather be ethical, responsible, and accountable.